Seres Therapeutics (MCRB) Tops Q2 EPS by 5c

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.22), $0.05 better than the analyst estimate of ($0.27).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Citigroup set to join top banks in Anthropic IPO - Bloomberg
• Jefferies Downgrades Pop Mart International Group Ltd (9992:HK) to Hold
• JPMorgan Resumes Drax Group Plc. (DRX:LN) (DRXGY) at Overweight